XML 38 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Note 12 - Segment Reporting
12 Months Ended
Dec. 31, 2019
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
1
2
.  
Segment Reporting
 
The Company has
two
reportable segments, which are the same as its operating segments:
 
The Device Segment, engages in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. The device division is operated through the Company’s ThermoGenesis Corp. subsidiary.
 
The Clinical Development Segment, utilizes autologous (utilizing the patient’s own cells) stem cell-based therapeutics through the Company’s TotipotentRX subsidiary in Gurgaon, India.
 
The following table summarizes the operating results of the Company’s reportable segments:
 
   
Year Ended December 31, 2019
 
   
Device
   
Clinical Development
   
Total
 
Net revenues
  $
12,957,000
    $
90,000
    $
13,047,000
 
Cost of revenues
   
7,175,000
     
176,000
     
7,351,000
 
Gross profit
   
5,782,000
     
(86,000
)    
5,696,000
 
                         
Operating expenses
   
7,081,000
     
3,348,000
     
10,429,000
 
Operating loss
  $
(1,299,000
)   $
(3,434,000
)   $
(4,733,000
)
                         
Depreciation and amortization
  $
530,000
    $
275,000
    $
805,000
 
Stock-based compensation expense
  $
393,000
    $
221,000
    $
614,000
 
Goodwill
  $
781,000
    $
--
    $
781,000
 
Total assets
  $
13,420,000
    $
1,794,000
    $
15,214,000
 
 
 
   
Year Ended December 31, 2018
 
   
Device
   
Clinical
Development
   
Total
 
Net revenues
  $
9,469,000
    $
203,000
    $
9,672,000
 
Cost of revenues
   
7,205,000
     
274,000
     
7,479,000
 
Gross profit
   
2,264,000
     
(71,000
)    
2,193,000
 
                         
Operating expenses
   
8,398,000
     
37,340,000
     
45,738,000
 
Operating loss
  $
(6,134,000
)   $
(37,411,000
)   $
(43,545,000
)
                         
Depreciation and amortization
  $
398,000
    $
272,000
    $
670,000
 
Stock-based compensation expense
  $
179,000
    $
473,000
    $
652,000
 
Goodwill
  $
781,000
     
--
    $
781,000
 
Total assets
  $
10,815,000
    $
3,796,000
    $
14,611,000
 
 
The Company had sales in the following geographical areas for the:
 
   
Year Ended December 31,
 
   
2019
   
2018
 
United States
  $
6,787,000
    $
4,854,000
 
Asia – other
   
2,108,000
     
1,717,000
 
Europe
   
1,233,000
     
1,165,000
 
China
   
2,346,000
     
1,143,000
 
Other
   
573,000
     
793,000
 
    $
13,047,000
    $
9,672,000
 
 
The Company attributes revenue to different geographic areas based on where items are shipped, or services are performed.